NIH #1R01CA296285-01A1
Targeting the Epidermal Growth Factor Receptor (EGFR) to Revert Trastuzumab Deruxtecan Resistance in HER2-low Colorectal Cancer.
- Amount
- $482K
- Period
- 2025-08-01 → 2030-07-31
- PIs
- 2
- Est. capacity / PI
- ~3 students
Awarded at SLOAN-KETTERING INST CAN RESEARCH